Full Text Full Text (PDF) CME: Take the course for this article: Schizophrenia Synthesis Citation Map Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Marder, S. R. Search for Related Content Articles by Marder, S. R.

Neurocognition as a Treatment Target in Schizophrenia

Correspondence: Address Correspondence to: Stephen R. Marder, M.D., Building 210, Room 130, West Los Angeles VA Healthcare Center, 11301 Wilshire Boulevard, Los Angeles, CA 90073.

Recent attention has focused on the limitations of current antipsychotic medications for improving community functioning in schizophrenia. The strong relationship between neurocognition and functional outcome has led to a focus on developing pharmacological agents that improve cognition. The potential of this target led to a National Institute of Mental Health initiative known as Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS). Through a series of consensus meetings that included representatives from academia, the pharmaceutical industry, and government, this initiative has developed a consensus battery of neuropsychological tests that can be used as an outcome measure in clinical trials, a pathway to drug approval that has been endorsed by the U.S. Food and Drug Administration, a priority list of molecular targets for new drug development, and a consensus regarding the design of clinical trials.

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us